| Name | Title | Contact Details |
|---|
At Intouch Solutions, we know pharma marketing isn`t easy. But after more than a decade of hard work in this and similarly regulated industries, we think we understand that better than most. We have a pretty good idea of what it takes to connect your customers to your brand.
Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.
Myonexus Therapeutics is a clinical stage, rare disease gene therapy company developing first-ever, corrective treatments for Limb-girdle muscular dystrophy.
Design Therapeutics is a biotechnology company developing a new class of therapies for serious degenerative disorders caused by nucleotide repeat expansions.
Prospect Biosystems is a Newark, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.